<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822350</url>
  </required_header>
  <id_info>
    <org_study_id>B9991045</org_study_id>
    <nct_id>NCT04822350</nct_id>
  </id_info>
  <brief_title>A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA</brief_title>
  <acronym>AVENANCE</acronym>
  <official_title>AVENANCE - A Non-interventional Study to Provide Real-world Data on the Use of Avelumab as a Maintenance Treatment for Patients With Advanced or Metastatic Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter ambispective (retrospective and prospective) non-interventional study of&#xD;
      patients with locally advanced or metastatic urothelial carcinoma (adv/mUC) treated with&#xD;
      avelumab in France, not impacting the treatment decision made by the treating physician and&#xD;
      the medical management of treated patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>time between the first injection of avelumab and the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall Survival from the start of the chemotherapy used in 1st line</measure>
    <time_frame>1st line Chemotherapy start up to 4 years</time_frame>
    <description>time between the first injection of the chemotherapy used in 1st line and the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival 1</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>time between the first injection of avelumab and the date of progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival 2</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>time between the first injection of avelumab and the date of progression or death from any cause during the 2nd line of treatment post-avelumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>Complete Response or Partial Response as a best response during the avelumab treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>Beginning of response up to 4 years</time_frame>
    <description>time between the beginning of the response and progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of treatment</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>time between the first and last dose of avelumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of progression under avelumab</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>Metastatic sites and type of progression (new lesion(s)/progression of known lesion(s)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) reporting</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>Adverse events (AEs) of any type, grade 3-4 AEs, AEs leading to interruption or discontinuation, AEs leading to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premedications (acetaminophen and antihistamine)</measure>
    <time_frame>Avelumab initiation up to 4 years</time_frame>
    <description>Proportion of patients who received a premedication at each injection of avelumab. Median number of cycles with premedication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>Initiation of avelumab, 6 weeks, 3 months, and every three months for up to 2 years</time_frame>
    <description>Evolution of PROs NCCN/FACT FBlSI-18 and EQ-5D-5L scores during avelumab treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate on subsequent treatments</measure>
    <time_frame>Discontinuation of avelumab up to 4 years</time_frame>
    <description>Complete Response or Partial Response as a best response during the subsequent treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of subsequent treatments</measure>
    <time_frame>Discontinuation of avelumab up to 4 years</time_frame>
    <description>time between the first and last dose of subsequent treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival on subsequent treatments</measure>
    <time_frame>Discontinuation of avelumab up to 4 years</time_frame>
    <description>time between the first dose of subsequent treatment and the date of progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival on subsequent treatments</measure>
    <time_frame>Discontinuation of avelumab up to 4 years</time_frame>
    <description>time between the first dose of subsequent treatment and the date of death from any cause</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Locally advanced or metastatic urothelial carcinoma patients treated with avelumab</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>As provided in real world practice</description>
    <arm_group_label>Locally advanced or metastatic urothelial carcinoma patients treated with avelumab</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced or metastatic Urothelial Carcinoma treated with avelumab as a&#xD;
        maintenance treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient â‰¥ 18 years of age&#xD;
&#xD;
          2. Patient with locally advanced or metastatic urothelial carcinoma (irrespective of&#xD;
             tumor histology) whose disease has not progressed (ongoing stable disease, partial&#xD;
             response or complete response) following completion of first-line platinum-based&#xD;
             chemotherapy and who has been (restrospective), is (retropsectifve and prospective),&#xD;
             will be (prospective) treated with avelumab.&#xD;
&#xD;
               -  For a patient alive at the moment of the inclusion in the study : the patient&#xD;
                  must be informed of the study, he/she must be given an information letter signed&#xD;
                  by the investigator and must not be opposed to the collection of his/her data&#xD;
&#xD;
               -  For a patient who died before the inclusion in the study : the family of the&#xD;
                  patient must be informed and the patient (during his lifetime) must not be&#xD;
                  opposed to the collection of his data.&#xD;
&#xD;
          3. Patient benefiting from a social security scheme according to local regulations&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          4. For a patient alive at the moment of the inclusion in the study: patient without&#xD;
             liberty, under tutelage, or unable to give oral consent.&#xD;
&#xD;
          5. Patient enrolled in a prospective interventional clinical trial assessing an&#xD;
             investigational product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil Cedex</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Georges</name>
      <address>
        <city>Nice</city>
        <zip>06105</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique mutualiste de l Estuaire</name>
      <address>
        <city>Saint Nazaire Cedex</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B9991045</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avelumab</keyword>
  <keyword>Non-interventional study</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>France</keyword>
  <keyword>Maintenance</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

